Comparator Study of LT-NS001 in Healthy Subjects With Endoscopic Evaluation
Information source: Logical Therapeutics
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: LT-NS001 (Drug); Naprosyn® (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Logical Therapeutics
Summary
The purpose of this study is to compare naproxen plasma levels and gastroduodenal mucosal
injury after administration of LT-NS001 as compared to Naprosyn in subjects age 45-70.
Clinical Details
Official title: A Double-Blind, Randomized, Active Comparator Study of LT-NS001 Versus Naprosyn for Seven Days in Healthy Subjects With Endoscopic Evaluation
Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary outcome: Assessment of GI mucosal injury by endoscopy
Secondary outcome: Comparison of naproxen PK at steady state
Eligibility
Minimum age: 45 Years.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- BMI 18-30 kg/m2
- No NSAID's for 14 days prior to baseline endoscopy
Exclusion Criteria:
- Pregnant/Nursing women
- History of documented gastroduodenal ulcer
Locations and Contacts
University of Illinois at Chicago, Chicago, Illinois 60612, United States
Additional Information
Starting date: September 2008
Last updated: October 4, 2010
|